Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Conventional oncology cannot cure multiple myeloma. Repeated multiple myeloma chemotherapy regimens will result in remission, relapse, remission, relapse and multi-drug resistance I don’t want to sound negative but a multiple myeloma diagnosis is a death sentence eventually. The greatest challenge of the multiple myeloma (MM) patient then, is multi-drug resistence (MDR).
The good news is that conventional oncology has gotten pretty good at putting the newly diagnosed MM patient into remission. The challenge then, is for the patient to
If MM patients could reach remission repeatedly for the rest of their lives, then this incurable blood cancer really could become a chronic disease. Unfotunately, most MM patients eventually face MDR. Their MM no longer responds to therapy. Any therapy.
According to the studies linked and excerpted below, ART may be able to overcome MDR. Or to put it in the jargon of the study below “ART inhibits viability of MM cell lines and primary MM cells, regardless of prior drug resistance...” The critical phrase is “regardless of prior drug resistance.”
The drawback to the studies below is that they are in vitro aka in a test tube, and not in actual MM patients. Another potential drawback is that ART is not the standard-of-care for MM and therefore will not be know by your oncologist.
Have you been diagnosed with multiple myeloma? To learn more about conventional and evidence-based non-conventional therapies scroll down the page, post a question or comment and I will reply to you ASAP.
“Artesunate’s (ART) unique mechanism probably was at least partially responsible for, its ability to act synergistically with multiple anti-myeloma agents…
Nevertheless, treatment of patients diagnosed with high-risk MM  or those who relapse after exposure to a multitude of anti-MM agents remains a significant challenge…
“Nevertheless, over time many patients relapse and develop resistance to treatment, and efforts are needed to overcome drug resistance. The widely used malaria drug artesunate has been reported to have antitumor activity, and we aimed to test the effects of artesunate on a panel of myeloma and lymphoma cells…
RESULTS: ART treatment efficiently inhibited cell growth and induced apoptosis in cell lines…Furthermore, some primary myeloma cells were also sensitive to ART at doses around 10 μm. Concentrations of this order are pharmacologically relevant as they can be obtained in plasma after intravenous administration of ART for malaria treatment.
CONCLUSION: Our findings indicate that ART is a potential drug for treatment of multiple myeloma and DLBCL at doses of the same order as currently in use for treatment of malaria without serious adverse effects.”